Development of Tumor Organoids From Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
NCT ID: NCT06612827
Last Updated: 2025-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20 participants
OBSERVATIONAL
2025-03-05
2032-12-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood and tumor collection
Blood and tumor collection before treatment initiation
organoid etablishment
Prior to initiation of 1st-line therapy:
* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)
* A blood test blood a for tumoroid realization and :
* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo
* Analysis of correlation between in vivo and ex vivo tumor characteristics
* Analysis of first- and second-line survival rates and overall survival
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
organoid etablishment
Prior to initiation of 1st-line therapy:
* Collection of an additional study-specific tumor sample for tumoroid analysis (1 fresh tumor sample)
* A blood test blood a for tumoroid realization and :
* Analysis of ex vivo tumoroid response to treatment and correlation with patient response in vivo
* Analysis of correlation between in vivo and ex vivo tumor characteristics
* Analysis of first- and second-line survival rates and overall survival
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with indication for systemic 1st-line treatment at the time of inclusion. Treatment may already have begun at the time of inclusion, but within the limit of 2 treatment cycles administered.
* Patient with life expectancy greater than 3 months
* Patient of legal age
* Patient affiliated to a social security scheme
* Signature of informed consent prior to any specific study procedure
Exclusion Criteria
* Pregnant or breast-feeding patient
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Francois Baclesse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre François Baclesse
Caen, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Zoé NEVIERE, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-A01326-41
Identifier Type: -
Identifier Source: org_study_id